Sintilimab plus anlotinib before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (sintilimab and anlotinib) given before surgery to shrink tumors in people with early-stage lung cancer that can be removed. The goal is to see if this approach helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer (stage IB to IIIB) that can be removed with surgery.
- You have not received any treatment for your lung cancer yet.
- Your tumor does not have changes in the EGFR, ALK, or ROS1 genes.
- You are willing to have surgery to remove the cancer.
- You have good overall health and organ function (kidneys, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests a combination of chemotherapy and an immunotherapy drug called sintilimab to shrink unresectable stage IIIB-IIIC non-small cell lung cancer, making it possible to remove it with surgery. The goal is to see if this approach can help patients who aren't candidates for surgery now become candidates later.
This trial tests giving chemotherapy combined with the immunotherapy drug sintilimab before surgery for people with stage IIA to IIIB non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.